To determine the incidence, risk factors, and relative survival of acute myeloid leukemia (AML) secondary to myelodysplastic syndrome (MDS) in the Surveillance, Epidemiology, and End Results (SEER) database. Retrospective analysis of all patients with new MDS onset in the SEER-18 database from 2001 to 2013. We identified 36 558 patients with primary MDS. The rate of secondary AML (sAML) was 3.7% among patients 40 years or younger and 2.5% among those older than 40 (P = .039). The median transformation interval was significantly shorter for the younger group (4.04 vs 13.1 mo; P < .001). For both age groups, median overall and cancer-specific survival were significantly longer for patients who did not develop sAML. Although the younger patients survived longer than the older patients, sAML development had a more negative effect on the survival of younger patients. Female sex, age, and World Health Organization (WHO) type MDS with single lineage dysplasia (MDS-SLD) were associated with a decreased risk of sAML for older but not younger patients. Among older patients with MDS, a married status, Black race, female sex, shorter time to sAML, and WHO type MDS-SLD or MDS with ringed sideroblasts were favorable prognostic factors for survival. In the SEER database, the rate of sAML among patients with MDS is lower than that in previous reports, but these patients still have worse survival. Risk assessment should include clinical and demographic factors.
and MDS, unclassifiable (MDS-U). 1 Recent epidemiological studies of MDS in Asia, Europe, and the United States have reported divergent incidence rates of MDS ranging from less than 2 to more than 68 per 100 000 people, [2] [3] [4] [5] with a median survival of less than 3 years or 3-year survival of less than 60%. [6] [7] [8] [9] Management of MDS relies on diagnosis, classification, risk assessment, and treatment. 10 The Revised International Prognostic Scoring System (IPSS) (IPSS-R) 11 and WHO-based Prognostic Scoring System (WPSS) 12 are the most commonly used scoring systems, and the WPSS may be more useful for prediction of leukemia-free survival. 13 MDS can progress to secondary acute myeloid leukemia (sAML), which, currently, is defined as the presence of at least 20% blast cells.
The transformation process is most likely driven by successive rounds of mutation and clonal expansion within hematopoietic stem cells (HSCs) and blasts. 14 Mutations in Runt Related Transcription Factor 1 (RUNX1) have been associated with an increased risk of transformation to sAML. 15 sAML is unique from de novo AML and is associated with a poorer response to induction chemotherapy and decreased survival. 16 Recent analyses of two European registries have indicated that sAML causes one-third to one-half of disease-related deaths among patients with MDS. 17, 18 Although research conducted over the last 5 to 10 years has expanded our knowledge of the underlying genetic causes of MDS and progression to sAML, the incidence and relative survival data are becoming out of date. Moreover, limited information is available regarding the clinical or demographic factors that contribute to these conditions. To fill these gaps in knowledge, we conducted a retrospective study of the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) database. Since 1973, the SEER Program has collected demographic and clinical data from cancer registries that span almost one-third of the US population. The size of the SEER database makes it an excellent registry for relatively uncommon cancers, such as MDS. 19, 20 2 | PATIENTS AND METHODS
| Data source and ethics statement
This study analyzed data from the SEER Program, which is a collection of state or regional population-based cancer registries established by 
| Study population
This study included all patients in the database who received a new diagnosis of MDS between January 1, 2001, and December 31, 2013.
MDS was defined according to the WHO's Classification of Tumors of
Hematopoietic and Lymphoid Tissues (2016). Patients were stratified by age into two groups: those aged 40 years or younger and those older than 40 years.
| Study variables
The primary endpoint of the present study was the incidence of leukemic transformation, specifically AML, and its respective transformation time interval. We used the following ICD-O-3. 
| Statistical analysis
Comparability among the two age groups was tested using an independent two-sample t test for continuous variables and the Chi-square test for categorical variables. Continuous variables are represented as the mean and standard deviation (SD); categorical data are represented as the number count (n) and percentage (%). If continuous variables were obviously not normally distributed, the nonparametric Mann-Whitney U test was used, and the data are represented as the median and interquartile range (IQR). The Kaplan-Meier method with the log-rank test was used to compare OS and CSS between groups. A logistic regression analysis was performed to determine the significant risk factors associated with transformation of MDS into AML. In addition, a Cox proportional hazard regression model was built for analysis of prognostic factors for the survival outcomes of the included patients. All P values were two-sided, and values less than.05 were considered statistically significant. The statistical analyses were performed using the statistical software package SPSS version 22 (IBM, Armonk, NY, USA). The median OS for the total patients were 32 months, and the median OS between younger and older patients were significantly different (not reached vs 32 months). Moreover, the median OS was significantly shorter for the patients with sAML than for those without sAML (22 vs 33 months, P = .009). Figure 1 shows the OS (Figure 1A , B) and CSS rates ( Figure 1C ,D) among patients with or without sAML.
| RESULTS

| Study population
Significant differences in both OS ( Figure 1A ) and CSS ( Figure 1C) were found for the younger patients (P < .001). The median OS and CSS for the younger patients who did develop sAML were both 22 months, whereas the median OS and CSS were not reached for the younger patients with MDS that did not transform to AML.
Among the patients in the older group, the median OS was significantly shorter for the patients with sAML than for those without sAML (22 vs 32 months, P < .001, Figure 1B ). Moreover, older patients with sAML also had significantly shorter CSS than those who did not (23 vs 80 months, P < .001, Figure 1D ). When comparing patients in the younger and older groups, our analysis indicated that OS and CSS were similar for patients who developed sAML; however, for those who did not, the younger patients had longer OS and CSS than the older patients. 
| Analysis of risk factors for transformation to AML
| Analysis of factors associated with survival
We performed uni-and multivariate analyses with time-dependent Cox proportional hazard models to identify clinical and demographic factors associated with survival. Our results are shown in Tables 3 and   4 . Univariate analysis of both OS and CSS revealed that age, sex, 
| DISCUSSION
MDS is a group of heterogeneous myeloid clonal diseases with a risk of transformation to AML. Available data on the incidence, survival, and risk factors of sAML are not up-to-date. To shed light on these issues, we conducted a retrospective study of the SEER database. We analyzed data for more than 36 000 patients with MDS; as such, this study provides a valuable update to the field. We determined that the incidence of sAML was less than 5% and that the time interval to leukemic transformation ranged from months to years. However, patients younger than 40 years had a significantly higher incidence of sAML and developed sAML much more quickly than older patients.
We also report the novel finding that marital status and race are significant predictors of OS and CSS. Finally, our study confirms the negative impact of male sex, older age, and sAML on overall and CSS. Use of the SEER database has allowed us to update and substantially expand upon previous studies of the sAML incidence and the clinical and demographic risk factors associated with its development.
The size of the population we included (36 000) is among the largest of any population-based study of MDS or sAML, and this feature of our research provides a high level of reliability. We found that the overall rate of sAML was 3.7% among younger patients and 2.5% for older patients. These rates are much lower than the historically cited rates of 15% to 30%. Several factors could have contributed to this difference in the sAML rates. First, the MDS type at highest risk for transformation (MDS-EB) comprised just 13% of our population; second, we have not taken into account the effects of treatment on progression to sAML.
To the best of our knowledge, our study is the first to use a population-based registry to determine the time interval for transformation to AML. The median intervals observed among the 942 patients who progressed to AML in our study and reported remarkably similar OS times for the two age groups. 25, 26 The median survival of the younger groups was almost twice that of the older groups (39 and 40 mo vs 19 and 23 mo, respectively). Our analysis revealed that superior OS among younger patients was seen only for those who did not develop sAML. Younger patients with sAML had poor OS and CSS that was similar to that of older patients with sAML. In addition, younger patients developed sAML more quickly than older patients. Importantly, the transformation interval is shorter for younger patients even though older patients have a greater burden of comorbidities. 27 Younger patients are also more likely to undergo cytogenic assessment and risk stratification and receive active therapies, including stem cell transplantation. 28 However, our research lacked the mentioned above. Accordingly, we suggest that young patients who develop sAML may comprise a unique clinical population.
This study is also the first to assess the influence of marital status on the outcomes of patients with MDS. We found that married patients had significantly better OS and CSS than those who were revealed that the survival of married patients is significantly better than that of nonmarried patients for several types of cancer. [29] [30] [31] Because the population we assessed was more than 80% White, the effect of marital status could be race-specific. Recent studies by Martinez et al support this idea, because these authors found that race had a significant influence on the effect of marital status on allcause and cancer-specific mortality among 800 000 patients in the California Cancer Registry (CCR). 31 The most viable explanations for the effect of marriage on survival are that married patients have more support (emotionally, physically, or financially) or are less likely to make lifestyle choices that are detrimental to their health. 32 In conclusion, we conducted a retrospective analysis of the SEER cancer registry database. Our results indicate that although only a small percentage of patients with MDS go on to develop AML, these patients have significantly poorer survival than those without sAML, especially for those younger than 40 years. Survival of patients with MDS is influenced by demographic factors, including race, marital status, age, and sex. Accordingly, the accuracy of current risk assessment systems may be improved by including these types of data. 
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